» Articles » PMID: 1234503

Immediate Effects on Human Performance of a 1,5-genzodiazepine (clobazam) Compared with the 1,4-benzodiazepines, Chlordiazepoxide Hydrochloride and Diazepam

Overview
Specialty Pharmacology
Date 1975 Jun 1
PMID 1234503
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

1 The immediate effects on human performance of the 1,5-benzodiazepine, clobazam (20 mg), and the 1,4-benzodiazepines, chlordiazepoxide hydrochloride (20 mg) and diazepam (10 mg), were studied by adaptive tracking and measurement of reaction time. Each drug was ingested at 09.00 h and performance was measured at 09 h 30 min (0.5 h), 11 h 30 min (2.5 h), 14 h 30 min (5.5 h) and 18 h 30 min (9.5 h after ingestion). 2 With diazepam decrements in performance on adaptive tracking were observed at 0.5 h and 2.5 h and performance was enhanced at 9.5 h after ingestion. With clobazam performance at individual times did not differ significantly from control, but there was evidence of an improvement in performance during the day. There was no evidence of impaired performance on adaptive tracking after chlordiazepoxide hydrochloride. 3 Reaction time was slowed at 0.5 h and 2.5 h after diazepam and chlordiazepoxide hydrochloride. A decrease in reaction time was observed at 9.5 h after diazepam. No changes in reaction time were observed after clobazam. 4 The subjects as a group differentiated correctly between performance decrements on adaptive tracking after diazepam and the absence of performance decrements after clobazam and chlordiazepoxide hydrochloride. The persistence of the decrement in performance after diazepam was accurately assessed. 5 It is evident that the nature and persistence of impaired performance and the ability to appreciate impaired performance vary considerably between the benzodiazepines, and that the choice of a benzodiazepine should include careful consideration of performance sequelae.

Citing Articles

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Baakman A, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O Br J Clin Pharmacol. 2021; 88(6):2814-2829.

PMID: 34964149 PMC: 9306507. DOI: 10.1111/bcp.15206.


Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.

Faulkner M Ther Clin Risk Manag. 2015; 11:905-14.

PMID: 26089675 PMC: 4467745. DOI: 10.2147/TCRM.S55930.


Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series.

Sankar R, Chung S, Perry M, Kuzniecky R, Sinha S J Med Case Rep. 2014; 8:429.

PMID: 25511520 PMC: 4302143. DOI: 10.1186/1752-1947-8-429.


Effect of a metabolite of diazepam, 3-hydroxydiazepam (temazepam), on sleep in man.

Nicholson A, Stone B Br J Clin Pharmacol. 2012; 3(4):543-50.

PMID: 22216492 PMC: 1428905. DOI: 10.1111/j.1365-2125.1976.tb04873.x.


Effect of diazepam and fosazepam (a soluble derivative of diazepam) on sleep in man.

Nicholson A, Stone B, Clarke C Br J Clin Pharmacol. 2012; 3(4):533-41.

PMID: 22216491 PMC: 1428904. DOI: 10.1111/j.1365-2125.1976.tb04872.x.


References
1.
Rieder J . Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man. Arzneimittelforschung. 1973; 23(2):212-8. View

2.
Barzaghi F, Fournex R, Mantegazza P . Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung. 1973; 23(5):683-6. View

3.
MONTAGU J . Effects of diazepam on the EEG in man. Eur J Pharmacol. 1972; 17(1):167-70. DOI: 10.1016/0014-2999(72)90284-1. View

4.
de Silva J, KOECHLIN B, Bader G . Blood level distribution patterns of diazepam and its major metabolite in man. J Pharm Sci. 1966; 55(7):692-702. DOI: 10.1002/jps.2600550706. View

5.
Borland R, Nicholson A, Wright C . Behavioural sequelae of methaqualone in man and in the monkey (Macaca mulatta). Br J Clin Pharmacol. 1975; 2(2):131-41. PMC: 1402519. DOI: 10.1111/j.1365-2125.1975.tb01568.x. View